GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...
When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...
Industry leaders met in San Diego to debate whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, ...
Building an AI infrastructure for biotech. Bacteria that munch on cancer. How to best make a cold brew. All that and more in ...
Promoted by Dr Krishna Ella, the vaccine manufacturer serves both domestic and export markets and remains entirely ...
Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl. Cyprium is also obligated to pay 20% of ...
Neva is pleased to unveil further opportunities as a true collaborator for early-stage pharma/biotech innovators.
Vaccine developer Bharat Biotech International Ltd is mulling over a public listing that is expected to raise over $500 ...
Zacks Investment Research on MSN
Puma Biotech (PBYI) Q4 earnings and revenues beat estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago. These figures ...
Come to the Biotech Career & Futures Fair, where representatives of top biotech and biopharmaceutical companies will discuss their current and future job openings. The event is open to all Wake Tech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results